Sang Taek Kim, MD, PhD
Next Available Appointment
Call the Care center at 1-877-YALEMDS (1-877-925-3637)
Titles
- Assistant Professor
Education & Training
- PhDYale Graduate School of Arts and Sciences, Human Immunology (2014)
- Research FellowshipFred Hutchinson Cancer Research Center (2006)
- Research FellowshipYonsei University College of Medicine (2004)
- MDYonsei University (2003)
- BAYonsei University College of Science, Premedicine (1999)
Additional Information
Publications
- Li Y, Msaouel P, Campbell M, Hwu P, Diab A, Kim S. Successful management of pre-existing psoriatic arthritis through targeting the IL-23/IL-17 axis in cancer patients receiving immune checkpoint inhibitor therapy: a case series. RMD Open 2024, 10: e004308. PMID: 39214611, PMCID: PMC11367333, DOI: 10.1136/rmdopen-2024-004308.
- Kim S, Chu Y, Misoi M, Suarez-Almazor M, Tayar J, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu S, Wang J, Shah A, Tannir N, Campbell M, Gibbons D, Cascone T, Lu C, Blumenschein G, Altan M, Lim B, Valero V, Loghin M, Tu J, Westin S, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi H, Hwu P, Oliva I, Davies M, Patel S, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nature Communications 2024, 15: 5621. PMID: 38965214, PMCID: PMC11224259, DOI: 10.1038/s41467-024-49733-9.
- Turner N, Hamidi S, Ouni R, Rico R, Henderson Y, Puche M, Alekseev S, Colunga-Minutti J, Zafereo M, Lai S, Kim S, Cabanillas M, Nurieva R. Emerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy. Frontiers In Immunology 2024, 15: 1369780. PMID: 38868771, PMCID: PMC11167082, DOI: 10.3389/fimmu.2024.1369780.
- Bracamonte-Baran W, Kim S. The Current and Future of Biomarkers of Immune Related Adverse Events. Rheumatic Disease Clinics Of North America 2024, 50: 201-227. PMID: 38670721, PMCID: PMC11232920, DOI: 10.1016/j.rdc.2024.01.004.
- Aminu M, Daver N, Godoy M, Shroff G, Wu C, Torre-Sada L, Goizueta A, Shannon V, Faiz S, Altan M, Garcia-Manero G, Kantarjian H, Ravandi-Kashani F, Kadia T, Konopleva M, DiNardo C, Pierce S, Naing A, Kim S, Kontoyiannis D, Khawaja F, Chung C, Wu J, Sheshadri A. Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept. Frontiers In Immunology 2023, 14: 1249511. PMID: 37841255, PMCID: PMC10570510, DOI: 10.3389/fimmu.2023.1249511.
- Lopez-Olivo M, Kachira J, Buni M, Kim S, Lu H, Tayar J, Duhon G, Ruiz J, Bingham C, Calabrese C, Volk R, Suarez-Almazor M. Learning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors. Cancers 2023, 15: 4004. PMID: 37568819, PMCID: PMC10416973, DOI: 10.3390/cancers15154004.
- Altan M, Soto F, Xu T, Wilson N, Franco-Vega M, Clavijo C, Shannon V, Faiz S, Gandhi S, Lin S, Lopez P, Zhong L, Akhmedzhanov F, Godoy M, Shroff G, Wu J, Khawaja F, Kim S, Naing A, Heymach J, Daniel-Macdougall C, Liao Z, Sheshadri A. Pneumonitis After Concurrent Chemoradiation and Immune Checkpoint Inhibition in Patients with Locally Advanced Non-small Cell Lung Cancer. Clinical Oncology 2023, 35: 630-639. PMID: 37507279, DOI: 10.1016/j.clon.2023.07.003.
- Ostrin E, Rider N, Alousi A, Irajizad E, Li L, Peng Q, Kim S, Bashoura L, Arain M, Noor L, Patel N, Mehta R, Popat U, Hosing C, Jenq R, Rondon G, Hanash S, Paczesny S, Shpall E, Champlin R, Dickey B, Sheshadri A. A Nasal Inflammatory Cytokine Signature Is Associated with Early Graft-versus-Host Disease of the Lung after Allogeneic Hematopoietic Cell Transplantation: Proof of Concept. ImmunoHorizons 2023, 7: 421-430. PMID: 37289498, PMCID: PMC10491477, DOI: 10.4049/immunohorizons.2300031.
- Soto F, Torre-Sada L, Mott F, Kim S, Nurieva R, Nagarajan P, Guo M, Shannon V, Faiz S, Casal R, Altan M, Lin J, Sheshadri A. Sarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature. Journal Of Immunotherapy And Precision Oncology 2023, 6: 111-116. PMID: 37214206, PMCID: PMC10195014, DOI: 10.36401/jipo-22-30.
- Kim S, Bowman S, Lu H. Rheumatology (Arthritis and Myositis). 2022, 301-313. DOI: 10.1007/978-3-031-00241-0_15.
- Hailemichael Y, Johnson D, Abdel-Wahab N, Foo W, Bentebibel S, Daher M, Haymaker C, Wani K, Saberian C, Ogata D, Kim S, Nurieva R, Lazar A, Abu-Sbeih H, Fa'ak F, Mathew A, Wang Y, Falohun A, Trinh V, Zobniw C, Spillson C, Burks J, Awiwi M, Elsayes K, Soto L, Melendez B, Davies M, Wargo J, Curry J, Yee C, Lizee G, Singh S, Sharma P, Allison J, Hwu P, Ekmekcioglu S, Diab A. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell 2022, 40: 509-523.e6. PMID: 35537412, PMCID: PMC9221568, DOI: 10.1016/j.ccell.2022.04.004.
- Nurieva R, Zhao Y, Alekseev A, Galkina E, Kim S. Role of Grail in intestinal inflammation. The Journal Of Immunology 2022, 208: 111.27-111.27. DOI: 10.4049/jimmunol.208.supp.111.27.
- Sheshadri A, Goizueta A, Shannon V, London D, Garcia‐Manero G, Kantarjian H, Ravandi‐Kashani F, Kadia T, Konopleva M, DiNardo C, Pierce S, Zarifa A, Albittar A, Zhong L, Akhmedzhanov F, Arain M, Alfayez M, Alotaibi A, Altan M, Naing A, Mendoza T, Godoy M, Shroff G, Kim S, Faiz S, Kontoyiannis D, Khawaja F, Jennings K, Daver N. Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study. Cancer 2022, 128: 2736-2745. PMID: 35452134, PMCID: PMC9232977, DOI: 10.1002/cncr.34229.
- Kim S, Chu Y, Misoi M, Suarez-Almazor M, Tayar J, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu S, Wang J, Shah A, Tannir N, Campbell M, Gibbons D, Cascone T, Lu C, Blumenschein G, Altan M, Lim B, Valero V, Loghin M, Tu J, Westin S, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi H, Hwu P, Oliva I, Davies M, Patel S, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nature Communications 2022, 13: 1970. PMID: 35413951, PMCID: PMC9005525, DOI: 10.1038/s41467-022-29539-3.
- Ouni R, Henderson Y, Chen Y, Turner N, Padron W, Dadbin A, McBeath Fujiwara E, Wang J, Cabanillas M, Dadu R, Hofmann M, Zafereo M, Kim S, Lai S, Nurieva R. Characterization of Altered immunity in Anaplastic Thyroid Cancer. 2022 DOI: 10.52519/00072.
- Rodriguez E, Pei G, Zhao Z, Kim S, German A, Robinson P. Erratum: Rodriguez et al. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers 2021, 13, 3871. Cancers 2021, 13: 5178. PMID: 34680400, PMCID: PMC8533910, DOI: 10.3390/cancers13205178.
- Rodriguez E, Pei G, Zhao Z, Kim S, German A, Robinson P. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers 2021, 13: 3871. PMID: 34359773, PMCID: PMC8345440, DOI: 10.3390/cancers13153871.
- Kim S, Tayar J, Fu S, Ke D, Norry E, Sun A, Miller J, Hong D. Newly developed pseudogout arthritis after therapy with MAGE-A4 directed TCR T cells responded to treatment with tocilizumab. Journal For ImmunoTherapy Of Cancer 2021, 9: e002716. PMID: 34233963, PMCID: PMC8264871, DOI: 10.1136/jitc-2021-002716.
- Kim S, Pundole X, Dadu R, Lambotte O, Ramos-Casals M, Suarez-Almazor M. Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis. Immunotherapy 2021, 13: 465-475. PMID: 33641345, PMCID: PMC7983044, DOI: 10.2217/imt-2020-0272.
- Nurieva R, Divenko M, Kim S. Cancer Immunology and the Evolution of Immunotherapy. 2021, 3-29. DOI: 10.1007/978-3-030-56824-5_1.
- Kim ST, Sheshadri A, Shannon V, Kontoyiannis DP, Kantarjian H, Garcia-Manero G, Ravandi F, Im JS, Boddu P, Bashoura L, Balachandran DD, Evans SE, Faiz S, Vazquez W, Divenko M, Mathur R, Tippen SP, Gumbs C, Neelapu SS, Naing A, Wang L, Diab A, Futreal A, Nurieva R, Daver N. Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications. Frontiers In Immunology 2021, 11: 590494. PMID: 33552049, PMCID: PMC7859512, DOI: 10.3389/fimmu.2020.590494.
- Abdel-Wahab N, Diab A, Katayama H, Kim S, Hanash S, Suarez-Almazor M. 638 Plasma proteome analysis in patients with immune checkpoint inhibitors related arthritis and pneumonitis. Journal For ImmunoTherapy Of Cancer 2020, 8: a674-a674. DOI: 10.1136/jitc-2020-sitc2020.0638.
- Saberian C, Fa’ak F, Tayar J, Buni M, Kim S, Lu H, Suarez-Almazor M, Gruschkus S, Daher M, Ludford K, Johnson D, Abdel-Wahab N, Diab A. 657 Interleukin-6 receptor blockade for management of immune checkpoint inhibitor related adverse events in patients with melanoma. Journal For ImmunoTherapy Of Cancer 2020, 8: a394-a394. DOI: 10.1136/jitc-2020-sitc2020.0657.
- Kim S, Murphy W, Aparicio A, Subudhi S. RS3PE Following Treatment With Combination of Hormonal Therapies Plus Ipilimumab in a Patient With Metastatic Prostate Cancer. Journal Of Immunotherapy And Precision Oncology 2020, 3: 128-132. PMID: 35663254, PMCID: PMC9165580, DOI: 10.36401/jipo-20-2.
- Bedrose S, Turin C, Lavis V, Kim S, Thosani S. A Case of Acquired Generalized Lipodystrophy Associated with Pembrolizumab in a Patient with Metastatic Malignant Melanoma. AACE Clinical Case Reports 2020, 6: e40-e45. PMID: 32524008, PMCID: PMC7279776, DOI: 10.4158/accr-2019-0234.
- Kim S, Bittar M, Kim H, Neelapu S, Zurita A, Nurieva R, Suarez-Almazor M. Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare. Journal For ImmunoTherapy Of Cancer 2019, 7: 126. PMID: 31088575, PMCID: PMC6518723, DOI: 10.1186/s40425-019-0597-x.
- Ahn S, Kwon M, Sung M, Jung S, Lee S, Park Y, Kim S, Song J. Ex Vivo Interferon Gamma Production by Peripheral Immune Cells Predicts Survival in Lung Adenocarcinoma. Clinical Lung Cancer 2019, 20: e299-e308. PMID: 30824332, DOI: 10.1016/j.cllc.2019.01.002.
- Kim S, Suarez-Almazor M. Managing immune dysregulation resulting from immune checkpoint inhibitors: impact of the ASCO guidelines and key take-homes for immunologists. Expert Review Of Clinical Immunology 2018, 15: 211-213. PMID: 30589372, DOI: 10.1080/1744666x.2019.1559731.
- Kim S, Shannon V, Sheshadri A, Kantarjian H, Garcia-Manero G, Im J, Ravandi F, Naing A, Futreal A, Daver N. TH1/17 hybrid CD4+ cells in bronchial alveolar lavage fluid from leukemia patients with checkpoint inhibitor-induced pneumonitis. Journal Of Clinical Oncology 2018, 36: 204-204. DOI: 10.1200/jco.2018.36.5_suppl.204.
- Kim S, Shannon V, Sheshadri A, Kantarjian H, Garcia-Manero G, Im J, Ravandi F, Naing A, Sharma P, Kontoyiannis D, Futreal A, Daver N. Th1/17 Hybrid CD4+ Cells Are Expanded in Bronchial Alveolar Lavage Fluid from Leukemia Patients with Checkpoint Inhibitor-Induced Pneumonitis. Clinical Lymphoma Myeloma & Leukemia 2017, 17: s10. DOI: 10.1016/j.clml.2017.09.037.
- Kim S, Tayar J, Trinh V, Suarez-Almazor M, Garcia S, Hwu P, Johnson D, Uemura M, Diab A. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Annals Of The Rheumatic Diseases 2017, 76: 2061. PMID: 28830882, DOI: 10.1136/annrheumdis-2017-211560.
- Kim S, Diab A, Uemura M, Garcia S, Hwu P, Tayar J. FRI0604 Successful treatment of arthritis induced by checkpoint inhibitors with anti–interleukin-6 receptor antibody: a case series. 2017, 717.2-718. DOI: 10.1136/annrheumdis-2017-eular.6504.
- Suarez‐Almazor M, Kim S, Abdel‐Wahab N, Diab A. Review: Immune‐Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer. Arthritis & Rheumatology 2017, 69: 687-699. PMID: 28085999, DOI: 10.1002/art.40043.
- Bocchini C, Nahmod K, Katsonis P, Kim S, Kasembeli M, Freeman A, Lichtarge O, Makedonas G, Tweardy D. Protein stabilization improves STAT3 function in autosomal dominant hyper-IgE syndrome. Blood 2016, 128: 3061-3072. PMID: 27799162, PMCID: PMC5201093, DOI: 10.1182/blood-2016-02-702373.
- Choi J, Kim S, Kang I, Craft J. Aberant expansion of CXCR5+ memory CD4 T cells in SLE patients (HUM7P.307). The Journal Of Immunology 2014, 192: 184.16-184.16. DOI: 10.4049/jimmunol.192.supp.184.16.
- Choi J, Kim S, Kang I, Craft J. Aberrant expansion of CXCR5+ memory CD4 T cells in patients with systemic lupus erythematosus. Arthritis Research & Therapy 2014, 16: a20. PMCID: PMC4179526, DOI: 10.1186/ar4636.
- Kinnunen T, Chamberlain N, Morbach H, Choi J, Kim S, Craft J, Mayer L, Cancrini C, Passerini L, Bacchetta R, Ochs HD, Torgerson TR, Meffre E. Accumulation of peripheral autoreactive B cells in the absence of functional human regulatory T cells. Blood 2012, 121: 1595-1603. PMID: 23223361, PMCID: PMC3587322, DOI: 10.1182/blood-2012-09-457465.
- Poholek A, Choi J, Hernandez S, Weinstein J, Kim S, Bunin V, Odegard J, DiPlacido L, Craft J. Follicular helper T Cells and the B cells they help. Arthritis Research & Therapy 2012, 14: a2. PMCID: PMC3467479, DOI: 10.1186/ar3936.
- Choi J, Kim S, Lainez B, Craft J. Characterization of different subsets of human follicular helper T (TFH) cells (152.9). The Journal Of Immunology 2011, 186: 152.9-152.9. DOI: 10.4049/jimmunol.186.supp.152.9.
- Kim S, Choi J, DiPlacido L, Lainez B, Vlamakis V, Craft J. Characterization of Human Follicular Helper T (TFH) Cells. Clinical Immunology 2010, 135: s53. DOI: 10.1016/j.clim.2010.03.161.
Departments and Programs
Titles
- Assistant Professor
Education & Training
- PhDYale Graduate School of Arts and Sciences, Human Immunology (2014)
- Research FellowshipFred Hutchinson Cancer Research Center (2006)
- Research FellowshipYonsei University College of Medicine (2004)
- MDYonsei University (2003)
- BAYonsei University College of Science, Premedicine (1999)
Additional Information
Publications
- Li Y, Msaouel P, Campbell M, Hwu P, Diab A, Kim S. Successful management of pre-existing psoriatic arthritis through targeting the IL-23/IL-17 axis in cancer patients receiving immune checkpoint inhibitor therapy: a case series. RMD Open 2024, 10: e004308. PMID: 39214611, PMCID: PMC11367333, DOI: 10.1136/rmdopen-2024-004308.
- Kim S, Chu Y, Misoi M, Suarez-Almazor M, Tayar J, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu S, Wang J, Shah A, Tannir N, Campbell M, Gibbons D, Cascone T, Lu C, Blumenschein G, Altan M, Lim B, Valero V, Loghin M, Tu J, Westin S, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi H, Hwu P, Oliva I, Davies M, Patel S, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nature Communications 2024, 15: 5621. PMID: 38965214, PMCID: PMC11224259, DOI: 10.1038/s41467-024-49733-9.
- Turner N, Hamidi S, Ouni R, Rico R, Henderson Y, Puche M, Alekseev S, Colunga-Minutti J, Zafereo M, Lai S, Kim S, Cabanillas M, Nurieva R. Emerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy. Frontiers In Immunology 2024, 15: 1369780. PMID: 38868771, PMCID: PMC11167082, DOI: 10.3389/fimmu.2024.1369780.
- Bracamonte-Baran W, Kim S. The Current and Future of Biomarkers of Immune Related Adverse Events. Rheumatic Disease Clinics Of North America 2024, 50: 201-227. PMID: 38670721, PMCID: PMC11232920, DOI: 10.1016/j.rdc.2024.01.004.
- Aminu M, Daver N, Godoy M, Shroff G, Wu C, Torre-Sada L, Goizueta A, Shannon V, Faiz S, Altan M, Garcia-Manero G, Kantarjian H, Ravandi-Kashani F, Kadia T, Konopleva M, DiNardo C, Pierce S, Naing A, Kim S, Kontoyiannis D, Khawaja F, Chung C, Wu J, Sheshadri A. Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept. Frontiers In Immunology 2023, 14: 1249511. PMID: 37841255, PMCID: PMC10570510, DOI: 10.3389/fimmu.2023.1249511.
- Lopez-Olivo M, Kachira J, Buni M, Kim S, Lu H, Tayar J, Duhon G, Ruiz J, Bingham C, Calabrese C, Volk R, Suarez-Almazor M. Learning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors. Cancers 2023, 15: 4004. PMID: 37568819, PMCID: PMC10416973, DOI: 10.3390/cancers15154004.
- Altan M, Soto F, Xu T, Wilson N, Franco-Vega M, Clavijo C, Shannon V, Faiz S, Gandhi S, Lin S, Lopez P, Zhong L, Akhmedzhanov F, Godoy M, Shroff G, Wu J, Khawaja F, Kim S, Naing A, Heymach J, Daniel-Macdougall C, Liao Z, Sheshadri A. Pneumonitis After Concurrent Chemoradiation and Immune Checkpoint Inhibition in Patients with Locally Advanced Non-small Cell Lung Cancer. Clinical Oncology 2023, 35: 630-639. PMID: 37507279, DOI: 10.1016/j.clon.2023.07.003.
- Ostrin E, Rider N, Alousi A, Irajizad E, Li L, Peng Q, Kim S, Bashoura L, Arain M, Noor L, Patel N, Mehta R, Popat U, Hosing C, Jenq R, Rondon G, Hanash S, Paczesny S, Shpall E, Champlin R, Dickey B, Sheshadri A. A Nasal Inflammatory Cytokine Signature Is Associated with Early Graft-versus-Host Disease of the Lung after Allogeneic Hematopoietic Cell Transplantation: Proof of Concept. ImmunoHorizons 2023, 7: 421-430. PMID: 37289498, PMCID: PMC10491477, DOI: 10.4049/immunohorizons.2300031.
- Soto F, Torre-Sada L, Mott F, Kim S, Nurieva R, Nagarajan P, Guo M, Shannon V, Faiz S, Casal R, Altan M, Lin J, Sheshadri A. Sarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature. Journal Of Immunotherapy And Precision Oncology 2023, 6: 111-116. PMID: 37214206, PMCID: PMC10195014, DOI: 10.36401/jipo-22-30.
- Kim S, Bowman S, Lu H. Rheumatology (Arthritis and Myositis). 2022, 301-313. DOI: 10.1007/978-3-031-00241-0_15.
- Hailemichael Y, Johnson D, Abdel-Wahab N, Foo W, Bentebibel S, Daher M, Haymaker C, Wani K, Saberian C, Ogata D, Kim S, Nurieva R, Lazar A, Abu-Sbeih H, Fa'ak F, Mathew A, Wang Y, Falohun A, Trinh V, Zobniw C, Spillson C, Burks J, Awiwi M, Elsayes K, Soto L, Melendez B, Davies M, Wargo J, Curry J, Yee C, Lizee G, Singh S, Sharma P, Allison J, Hwu P, Ekmekcioglu S, Diab A. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell 2022, 40: 509-523.e6. PMID: 35537412, PMCID: PMC9221568, DOI: 10.1016/j.ccell.2022.04.004.
- Nurieva R, Zhao Y, Alekseev A, Galkina E, Kim S. Role of Grail in intestinal inflammation. The Journal Of Immunology 2022, 208: 111.27-111.27. DOI: 10.4049/jimmunol.208.supp.111.27.
- Sheshadri A, Goizueta A, Shannon V, London D, Garcia‐Manero G, Kantarjian H, Ravandi‐Kashani F, Kadia T, Konopleva M, DiNardo C, Pierce S, Zarifa A, Albittar A, Zhong L, Akhmedzhanov F, Arain M, Alfayez M, Alotaibi A, Altan M, Naing A, Mendoza T, Godoy M, Shroff G, Kim S, Faiz S, Kontoyiannis D, Khawaja F, Jennings K, Daver N. Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study. Cancer 2022, 128: 2736-2745. PMID: 35452134, PMCID: PMC9232977, DOI: 10.1002/cncr.34229.
- Kim S, Chu Y, Misoi M, Suarez-Almazor M, Tayar J, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu S, Wang J, Shah A, Tannir N, Campbell M, Gibbons D, Cascone T, Lu C, Blumenschein G, Altan M, Lim B, Valero V, Loghin M, Tu J, Westin S, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi H, Hwu P, Oliva I, Davies M, Patel S, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nature Communications 2022, 13: 1970. PMID: 35413951, PMCID: PMC9005525, DOI: 10.1038/s41467-022-29539-3.
- Ouni R, Henderson Y, Chen Y, Turner N, Padron W, Dadbin A, McBeath Fujiwara E, Wang J, Cabanillas M, Dadu R, Hofmann M, Zafereo M, Kim S, Lai S, Nurieva R. Characterization of Altered immunity in Anaplastic Thyroid Cancer. 2022 DOI: 10.52519/00072.
- Rodriguez E, Pei G, Zhao Z, Kim S, German A, Robinson P. Erratum: Rodriguez et al. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers 2021, 13, 3871. Cancers 2021, 13: 5178. PMID: 34680400, PMCID: PMC8533910, DOI: 10.3390/cancers13205178.
- Rodriguez E, Pei G, Zhao Z, Kim S, German A, Robinson P. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers 2021, 13: 3871. PMID: 34359773, PMCID: PMC8345440, DOI: 10.3390/cancers13153871.
- Kim S, Tayar J, Fu S, Ke D, Norry E, Sun A, Miller J, Hong D. Newly developed pseudogout arthritis after therapy with MAGE-A4 directed TCR T cells responded to treatment with tocilizumab. Journal For ImmunoTherapy Of Cancer 2021, 9: e002716. PMID: 34233963, PMCID: PMC8264871, DOI: 10.1136/jitc-2021-002716.
- Kim S, Pundole X, Dadu R, Lambotte O, Ramos-Casals M, Suarez-Almazor M. Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis. Immunotherapy 2021, 13: 465-475. PMID: 33641345, PMCID: PMC7983044, DOI: 10.2217/imt-2020-0272.
- Nurieva R, Divenko M, Kim S. Cancer Immunology and the Evolution of Immunotherapy. 2021, 3-29. DOI: 10.1007/978-3-030-56824-5_1.
- Kim ST, Sheshadri A, Shannon V, Kontoyiannis DP, Kantarjian H, Garcia-Manero G, Ravandi F, Im JS, Boddu P, Bashoura L, Balachandran DD, Evans SE, Faiz S, Vazquez W, Divenko M, Mathur R, Tippen SP, Gumbs C, Neelapu SS, Naing A, Wang L, Diab A, Futreal A, Nurieva R, Daver N. Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications. Frontiers In Immunology 2021, 11: 590494. PMID: 33552049, PMCID: PMC7859512, DOI: 10.3389/fimmu.2020.590494.
- Abdel-Wahab N, Diab A, Katayama H, Kim S, Hanash S, Suarez-Almazor M. 638 Plasma proteome analysis in patients with immune checkpoint inhibitors related arthritis and pneumonitis. Journal For ImmunoTherapy Of Cancer 2020, 8: a674-a674. DOI: 10.1136/jitc-2020-sitc2020.0638.
- Saberian C, Fa’ak F, Tayar J, Buni M, Kim S, Lu H, Suarez-Almazor M, Gruschkus S, Daher M, Ludford K, Johnson D, Abdel-Wahab N, Diab A. 657 Interleukin-6 receptor blockade for management of immune checkpoint inhibitor related adverse events in patients with melanoma. Journal For ImmunoTherapy Of Cancer 2020, 8: a394-a394. DOI: 10.1136/jitc-2020-sitc2020.0657.
- Kim S, Murphy W, Aparicio A, Subudhi S. RS3PE Following Treatment With Combination of Hormonal Therapies Plus Ipilimumab in a Patient With Metastatic Prostate Cancer. Journal Of Immunotherapy And Precision Oncology 2020, 3: 128-132. PMID: 35663254, PMCID: PMC9165580, DOI: 10.36401/jipo-20-2.
- Bedrose S, Turin C, Lavis V, Kim S, Thosani S. A Case of Acquired Generalized Lipodystrophy Associated with Pembrolizumab in a Patient with Metastatic Malignant Melanoma. AACE Clinical Case Reports 2020, 6: e40-e45. PMID: 32524008, PMCID: PMC7279776, DOI: 10.4158/accr-2019-0234.
- Kim S, Bittar M, Kim H, Neelapu S, Zurita A, Nurieva R, Suarez-Almazor M. Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare. Journal For ImmunoTherapy Of Cancer 2019, 7: 126. PMID: 31088575, PMCID: PMC6518723, DOI: 10.1186/s40425-019-0597-x.
- Ahn S, Kwon M, Sung M, Jung S, Lee S, Park Y, Kim S, Song J. Ex Vivo Interferon Gamma Production by Peripheral Immune Cells Predicts Survival in Lung Adenocarcinoma. Clinical Lung Cancer 2019, 20: e299-e308. PMID: 30824332, DOI: 10.1016/j.cllc.2019.01.002.
- Kim S, Suarez-Almazor M. Managing immune dysregulation resulting from immune checkpoint inhibitors: impact of the ASCO guidelines and key take-homes for immunologists. Expert Review Of Clinical Immunology 2018, 15: 211-213. PMID: 30589372, DOI: 10.1080/1744666x.2019.1559731.
- Kim S, Shannon V, Sheshadri A, Kantarjian H, Garcia-Manero G, Im J, Ravandi F, Naing A, Futreal A, Daver N. TH1/17 hybrid CD4+ cells in bronchial alveolar lavage fluid from leukemia patients with checkpoint inhibitor-induced pneumonitis. Journal Of Clinical Oncology 2018, 36: 204-204. DOI: 10.1200/jco.2018.36.5_suppl.204.
- Kim S, Shannon V, Sheshadri A, Kantarjian H, Garcia-Manero G, Im J, Ravandi F, Naing A, Sharma P, Kontoyiannis D, Futreal A, Daver N. Th1/17 Hybrid CD4+ Cells Are Expanded in Bronchial Alveolar Lavage Fluid from Leukemia Patients with Checkpoint Inhibitor-Induced Pneumonitis. Clinical Lymphoma Myeloma & Leukemia 2017, 17: s10. DOI: 10.1016/j.clml.2017.09.037.
- Kim S, Tayar J, Trinh V, Suarez-Almazor M, Garcia S, Hwu P, Johnson D, Uemura M, Diab A. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Annals Of The Rheumatic Diseases 2017, 76: 2061. PMID: 28830882, DOI: 10.1136/annrheumdis-2017-211560.
- Kim S, Diab A, Uemura M, Garcia S, Hwu P, Tayar J. FRI0604 Successful treatment of arthritis induced by checkpoint inhibitors with anti–interleukin-6 receptor antibody: a case series. 2017, 717.2-718. DOI: 10.1136/annrheumdis-2017-eular.6504.
- Suarez‐Almazor M, Kim S, Abdel‐Wahab N, Diab A. Review: Immune‐Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer. Arthritis & Rheumatology 2017, 69: 687-699. PMID: 28085999, DOI: 10.1002/art.40043.
- Bocchini C, Nahmod K, Katsonis P, Kim S, Kasembeli M, Freeman A, Lichtarge O, Makedonas G, Tweardy D. Protein stabilization improves STAT3 function in autosomal dominant hyper-IgE syndrome. Blood 2016, 128: 3061-3072. PMID: 27799162, PMCID: PMC5201093, DOI: 10.1182/blood-2016-02-702373.
- Choi J, Kim S, Kang I, Craft J. Aberant expansion of CXCR5+ memory CD4 T cells in SLE patients (HUM7P.307). The Journal Of Immunology 2014, 192: 184.16-184.16. DOI: 10.4049/jimmunol.192.supp.184.16.
- Choi J, Kim S, Kang I, Craft J. Aberrant expansion of CXCR5+ memory CD4 T cells in patients with systemic lupus erythematosus. Arthritis Research & Therapy 2014, 16: a20. PMCID: PMC4179526, DOI: 10.1186/ar4636.
- Kinnunen T, Chamberlain N, Morbach H, Choi J, Kim S, Craft J, Mayer L, Cancrini C, Passerini L, Bacchetta R, Ochs HD, Torgerson TR, Meffre E. Accumulation of peripheral autoreactive B cells in the absence of functional human regulatory T cells. Blood 2012, 121: 1595-1603. PMID: 23223361, PMCID: PMC3587322, DOI: 10.1182/blood-2012-09-457465.
- Poholek A, Choi J, Hernandez S, Weinstein J, Kim S, Bunin V, Odegard J, DiPlacido L, Craft J. Follicular helper T Cells and the B cells they help. Arthritis Research & Therapy 2012, 14: a2. PMCID: PMC3467479, DOI: 10.1186/ar3936.
- Choi J, Kim S, Lainez B, Craft J. Characterization of different subsets of human follicular helper T (TFH) cells (152.9). The Journal Of Immunology 2011, 186: 152.9-152.9. DOI: 10.4049/jimmunol.186.supp.152.9.
- Kim S, Choi J, DiPlacido L, Lainez B, Vlamakis V, Craft J. Characterization of Human Follicular Helper T (TFH) Cells. Clinical Immunology 2010, 135: s53. DOI: 10.1016/j.clim.2010.03.161.
Departments and Programs